

ASX ANNOUNCEMENT

AUA and SUFU release updated guidelines for surgical management of SUI patients

26 April 2017: Analytica Ltd (ASX: ALT), manufacturer of the PeriCoach® System, draws the attention of shareholders to a recent release of evidence-based clinical guidelines for the surgical treatment of stress urinary incontinence.

The guidelines are a joint release from the American Urological Association (AUA), a urological organisation with global influence, and the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU), an international organisation committed to enhancing pelvic medicine and reconstructive surgery.

The guidelines observe that the prevalence of SUI has been reported to be as high as 49%, and other sources¹ report that 30% of women with SUI will choose to undergo surgical procedures. The clear majority of such procedures are being done via midurethral slings, which have only been FDA approved since 1998 resulting in limited long term data.

The joint clinical surgical guideline provides 24 recommendations, consisting of areas around evaluations, discussion of risks as well as alternatives to surgical treatment options. For patients wishing to undergo treatment, the guidelines recommend non-surgical interventions including pelvic floor exercises as the first line of treatment. This conservative treatment includes discussion and evaluation of properly and consistently performing pelvic floor muscle exercise. These echo the guidelines issued in 2016 by the American College of Physicians.

The PeriCoach system provides biofeedback during pelvic floor exercise sessions and guides a patient through their exercise programme. The system records exercise frequency and pelvic floor muscle strength improvement to show the patient how she is improving with time, and the patient can elect to share this data with her urologist. This exercise record provides the surgeon with independently collected evidence that their patient has complied with their prescribed conservative treatment programme before deciding whether to proceed to surgery. For those patients that do proceed, this information can serve as another source of proof that appropriate clinical guidance was followed on the care pathway to surgical intervention, potentially mitigating legal action should a surgical risk come to fruition.

Analytica Chairman Dr. Michael Monsour said "All surgery carries risks, and these guidelines recommend that clinicians discuss conservative treatments in detail with patients before moving to surgery. Unfortunately, patient compliance with those conservative treatments has been almost impossible to measure until now. The PeriCoach system has the unique capability of providing the surgeon with independent evidence that the pelvic floor exercise part of their conservative treatment plan was followed by the patient. The data can also show the surgeon whether or not the clinically-relevant pelvic floor muscle strength has improved thanks to our patented force sensor arrangement.

"The costs of surgery and insurance are growing rapidly and with all litigation in this field, having evidence to back up your decisions is critical. The PeriCoach is the right product at the right time and should be an indispensable part of a urologist's workflow."

¹ Oliphant et al, Trends in SUI Inpatient Procedures in US, 1979-2004. Am J Obstet Gynecol. 2009 May



The full text of the evidence-based SUI guideline is now available online at:

[http://www.auanet.org/guidelines/stress-urinary-incontinence-\(sui\)](http://www.auanet.org/guidelines/stress-urinary-incontinence-(sui))

For more information, please contact: investorrelations@analyticamedical.com

For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit www.AnalyticaMedical.com

Follow us on:    

About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition. Strengthening of the pelvic floor muscles can also potentially improve sexual sensation or satisfaction and orgasm potential in some women.

PeriCoach has regulatory clearance in Australia, and has CE mark and USFDA 510(k) clearance. The product is available for sale from pericoach.com in Australia, New Zealand, UK and Ireland, and the USA.

